Biocon Biologics, a Biocon subsidiary, stated on Thursday that the integration of Viatris’ biosimilars business in 31 European nations was completed.
Following the acquisition of substantially all of Viatris’ global biosimilar business in November 2022, and the related integration of over 70 emerging market countries in July 2023 and North America in September 2023, the company said in a release that the full transition of Viatris’ biosimilars operations to Biocon Biologics Ltd in Europe represents another significant milestone.
Biocon Biologics has seven biosimilars in its portfolio in Europe, including Insulin Aspart, Bevacizumab, Adalimumab, Pegfilgrastim, Insulin Glargine, Trastuzumab, and Etanercept.
The integration of Viatris’ biosimilar business in Europe ahead of schedule is another significant milestone for Biocon Biologics in our journey to become a global biosimilars leader, said Shreehas Tambe, CEO & MD, Biocon Biologics.
At around 10.44 AM, Biocon was trading 1.34% higher at Rs 241.50, against the previous close of Rs 238.30 on NSE.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.